{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:33:13Z","timestamp":1770337993991,"version":"3.49.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Diabetes and hypertension are common among patients with airflow limitation and contribute to cardiovascular (CV) mortality, one of the leading causes of death among patients with airflow limitation.<\/jats:p>\n                    <jats:p>Objectives: Our goal was to examine the association of severity of airflow limitation with adherence to medications for hypertension and diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified 7,359 veterans with hypertension and\/or diabetes in the Veterans Integrated Service Network-20. Entry date into the cohort was defined as the date of a patient\u2019s first pulmonary function testing (PFT). Diagnostic codes (ICD-9), PFT, and pharmacy data were available via the electronic medical record or via direct interrogation of PFT equipment. Our primary exposure was airflow limitation defined as FEV1\u2009\u2265\u200980% predicted (normal), 80\u2009&amp;gt;\u2009FEV1\u2009\u2265\u200950% predicted (mild\/moderate), 50\u2009&amp;gt;\u2009FEV1\u2009\u2265\u200930% predicted (severe), and FEV1\u2009&amp;lt;\u200930% predicted (very severe). We assessed adherence using a validated method based on electronic pharmacy refill data and defined adherence as \u226580% medication possession for the period 6\u201312 months after enrollment. Medications of interest included \u03b2-blockers, calcium channel blockers, thiazides, and angiotensin-converting-enzyme inhibitors for patients with hypertension, and metformin and sulfonylureas for patients with diabetes. We used logistic regression models to assess the association between severity of airflow limitation and adherence, adjusted for demographics, health behaviors, and comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Overall adherence was poor (44.6\u201355.1%). Among patients with hypertension, when compared with subjects with normal FEV1, subjects with each category lower of FEV1 were less adherent to \u03b2-blockers, with an odds ratio (OR) of 0.87 (95% confidence interval [CI], 0.80\u20130.95); calcium channel blockers, with an OR of 0.83 (95% CI, 0.74\u20130.93); and angiotensin-converting-enzyme inhibitors with an OR of 0.91 (95% CI, 0.84\u20130.99). Airflow limitation was not associated with adherence to thiazides. Among patients with diabetes, we found no significant association of FEV1 with adherence, although a similar lower trend with increasing airflow limitation. In a sensitivity analysis limited to patients with chronic obstructive pulmonary disease, we found a nonstatistically significant trend for decreased adherence to \u03b2-blockers, calcium channel blockers, and angiotensin-converting-enzyme inhibitors in subjects with higher GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Severity of airflow limitation is associated with decreased adherence to \u03b2-blockers, calcium channel blockers, and angiotensin-converting-enzyme inhibitors. The decreased adherence to these medications may be related to adverse effects on symptoms in patients with lung disease, and may partially explain excess CV mortality in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.201501-001oc","type":"journal-article","created":{"date-parts":[[2015,4,7]],"date-time":"2015-04-07T16:58:12Z","timestamp":1428425892000},"page":"831-837","source":"Crossref","is-referenced-by-count":5,"title":["Adherence to Oral Medications for Hypertension and Diabetes in Veterans with Comorbid Airflow Limitation"],"prefix":"10.1093","volume":"12","author":[{"given":"Anne C.","family":"Melzer","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care, University of Washington and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Uman","sequence":"additional","affiliation":[{"name":"Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs Puget Sound, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Au","sequence":"additional","affiliation":[{"name":"Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs Puget Sound, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,6,1]]},"reference":[{"key":"2026012303401735500_bib1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1378\/chest.12-2847","article-title":"Cardiovascular comorbidity in COPD: systematic literature review","volume":"144","author":"M\u00fcllerova","year":"2013","journal-title":"Chest"},{"key":"2026012303401735500_bib2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1183\/09031936.00133805","article-title":"Mortality in COPD: role of comorbidities","volume":"28","author":"Sin","year":"2006","journal-title":"Eur Respir J"},{"key":"2026012303401735500_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/COPD.S6400","article-title":"Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity","volume":"4","author":"Finkelstein","year":"2009","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012303401735500_bib4","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1378\/chest.128.5.3198","article-title":"Factors associated with medication nonadherence in patients with COPD","volume":"128","author":"George","year":"2005","journal-title":"Chest"},{"key":"2026012303401735500_bib5","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/diacare.27.5.1218","article-title":"A systematic review of adherence with medications for diabetes","volume":"27","author":"Cramer","year":"2004","journal-title":"Diabetes Care"},{"key":"2026012303401735500_bib6","article-title":"Medication adherence for hypertension in patients with comorbid airflow limitation [abstract]","author":"Melzer","year":"2014"},{"key":"2026012303401735500_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MLR.0b013e3180329368","article-title":"A refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp)","volume":"45","author":"Bryson","year":"2007","journal-title":"Med Care"},{"key":"2026012303401735500_bib8","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1046\/j.1525-1497.2002.00406.x","article-title":"Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors","volume":"17","author":"Wang","year":"2002","journal-title":"J Gen Intern Med"},{"key":"2026012303401735500_bib9","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1345\/aph.1M570","article-title":"Refill adherence to oral hypoglycemic agents and glycemic control in veterans","volume":"44","author":"Kim","year":"2010","journal-title":"Ann Pharmacother"},{"key":"2026012303401735500_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1472-6963-11-37","article-title":"The validity of using ICD-9 codes and pharmacy records to identify patients with chronic obstructive pulmonary disease","volume":"11","author":"Cooke","year":"2011","journal-title":"BMC Health Serv Res"},{"key":"2026012303401735500_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.amjmed.2006.06.028","article-title":"Antihypertensive medication adherence in the Department of Veterans Affairs","volume":"120","author":"Siegel","year":"2007","journal-title":"Am J Med"},{"key":"2026012303401735500_bib12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.288.3.351","article-title":"\u03b2-Blocker therapy and symptoms of depression, fatigue, and sexual dysfunction","volume":"288","author":"Ko","year":"2002","journal-title":"JAMA"},{"key":"2026012303401735500_bib13","doi-asserted-by":"crossref","first-page":"II42","DOI":"10.1161\/01.HYP.11.3_Pt_2.II42","article-title":"Side effects of calcium channel blockers","volume":"11","author":"Russell","year":"1988","journal-title":"Hypertension"},{"key":"2026012303401735500_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2165\/00002018-199615010-00006","article-title":"ACE inhibitor\u2013induced cough and bronchospasm: incidence, mechanisms and management","volume":"15","author":"Overlack","year":"1996","journal-title":"Drug Saf"},{"key":"2026012303401735500_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1477-7525-2-51","article-title":"Multimorbidity and quality of life in primary care: a systematic review","volume":"2","author":"Fortin","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"2026012303401735500_bib16","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/0002-8703(91)90443-L","article-title":"Improving compliance and increasing control of hypertension: needs of special hypertensive populations","volume":"121","author":"Clark","year":"1991","journal-title":"Am Heart J"},{"key":"2026012303401735500_bib17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1524-6175.2007.06372.x","article-title":"Prevalence and predictors of poor antihypertensive medication adherence in an urban health clinic setting","volume":"9","author":"Hyre","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2026012303401735500_bib18","first-page":"814","article-title":"The implications of therapeutic complexity on adherence to cardiovascular medications","volume":"171","author":"Choudhry","year":"2011","journal-title":"Arch Intern Med"},{"key":"2026012303401735500_bib19","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1345\/aph.1C044","article-title":"Effect of number of medications on cardiovascular therapy adherence","volume":"36","author":"Shalansky","year":"2002","journal-title":"Ann Pharmacother"},{"key":"2026012303401735500_bib20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1592\/phco.20.11.941.35266","article-title":"The relationship between drug therapy noncompliance and patient characteristics, health-related quality of life, and health care costs","volume":"20","author":"Billups","year":"2000","journal-title":"Pharmacotherapy"},{"key":"2026012303401735500_bib21","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1378\/chest.12-1770","article-title":"Combination antihypertensive therapy among patients with COPD","volume":"143","author":"Herrin","year":"2013","journal-title":"Chest"},{"key":"2026012303401735500_bib22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1077558703060002007","article-title":"VHA enrollees\u2019 health care coverage and use of care","volume":"60","author":"Shen","year":"2003","journal-title":"Med Care Res Rev"},{"key":"2026012303401735500_bib23","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/MLR.0b013e3180ca95be","article-title":"Effect of increased copayments on pharmacy use in the Department of Veterans Affairs","volume":"45","author":"Stroupe","year":"2007","journal-title":"Med Care"},{"key":"2026012303401735500_bib24","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1164\/ajrccm.151.2.7842197","article-title":"Rapid decline in FEV1: a new risk factor for coronary heart disease mortality","volume":"151","author":"Tockman","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303401735500_bib25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.annepidem.2005.04.008","article-title":"Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada","volume":"16","author":"Curkendall","year":"2006","journal-title":"Ann Epidemiol"},{"key":"2026012303401735500_bib26","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/oxfordjournals.aje.a114483","article-title":"Peak expiratory flow and risk of cardiovascular disease and death: a 12-year follow-up of participants in the population study of women in Gothenburg, Sweden","volume":"124","author":"Persson","year":"1986","journal-title":"Am J Epidemiol"},{"key":"2026012303401735500_bib27","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/bmj.313.7059.711","article-title":"Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study","volume":"313","author":"Hole","year":"1996","journal-title":"BMJ"},{"key":"2026012303401735500_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0002-9343(97)00467-1","article-title":"Compliance with treatment regimens in chronic asymptomatic diseases","volume":"102","author":"Miller","year":"1997","journal-title":"Am J Med"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/12\/6\/831\/66446727\/annalsats_12_6_831.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/12\/6\/831\/66446727\/annalsats_12_6_831.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:40:27Z","timestamp":1769157627000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/12\/6\/831\/8429374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,1]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,1]]},"published-print":{"date-parts":[[2015,6,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.201501-001oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,6]]},"published":{"date-parts":[[2015,6,1]]}}}